📊 CGEM Key Takeaways
Is Cullinan Therapeutics, Inc. (CGEM) a Good Investment?
Cullinan Therapeutics is a pre-revenue biopharmaceutical company burning $46.1M annually in free cash flow with only $75.1M in cash on hand, implying ~1.6 years of runway at current burn rates. Zero revenue combined with significant operating losses (-$53.7M) and negative EPS (-$2.30) indicates the company has no commercial traction and faces a critical path dependency on securing additional funding or achieving major clinical/regulatory milestones to justify continued operations.
Cullinan Therapeutics has a strong balance sheet on paper, with high liquidity, no meaningful leverage, and equity far exceeding liabilities. However, the business remains fully pre-revenue and is consuming substantial cash, with deep operating and net losses and sharply worse per-share earnings, which weakens the fundamental outlook. Until the company demonstrates durable revenue generation or materially lower cash burn, the fundamentals remain unattractive.
Cullinan Therapeutics, Inc. Key Strengths (CGEM)
- Strong balance sheet with $75.1M cash and minimal liabilities ($36.8M)
- Excellent liquidity position with 10.28x current ratio and zero long-term debt
- Positive stockholders' equity of $366.2M provides cushion for near-term operations
- Very strong liquidity profile with current and quick ratios of 10.25x
- Debt-free balance sheet with low liabilities relative to equity
- Large asset and equity base provides financial flexibility versus many early-stage biotech peers
CGEM Stock Risks: Cullinan Therapeutics, Inc. Investment Risks
- Zero revenue indicates pre-commercial status or failed commercialization
- Annual cash burn of $46.1M reduces runway to approximately 1.6 years at current rate
- Significant operating losses (-$53.7M) and negative net income (-$49.7M) with no path to profitability visible
- Dilution risk from future financing needs to extend cash runway beyond current position
- No revenue generation or positive cash flow metrics visible in financial data
- No revenue generation, making the business entirely dependent on external funding or existing capital
- Heavy operating and free cash flow burn of roughly $176M annually
- Profitability metrics are deeply negative, with worsening diluted EPS indicating poor earnings quality
Key Metrics to Watch
- Quarterly cash burn trend and runway extension
- Clinical trial progress and regulatory milestones for pipeline programs
- Revenue generation timing and initial commercialization metrics
- Capital raise announcements and financing dilution impact
- Quarterly cash burn relative to cash and liquid resources
- Any transition from pre-revenue status to recurring collaboration, licensing, or product revenue
Cullinan Therapeutics, Inc. (CGEM) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 10.28x current ratio provides a solid financial cushion.
CGEM Profit Margin, ROE & Profitability Analysis
CGEM vs Healthcare Sector: How Cullinan Therapeutics, Inc. Compares
How Cullinan Therapeutics, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Cullinan Therapeutics, Inc. Stock Overvalued? CGEM Valuation Analysis 2026
Based on fundamental analysis, Cullinan Therapeutics, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Cullinan Therapeutics, Inc. Balance Sheet: CGEM Debt, Cash & Liquidity
CGEM Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Cullinan Therapeutics, Inc.'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $2.38 reflects profitable operations.
CGEM Revenue Growth, EPS Growth & YoY Performance
CGEM Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2022 | N/A | $1.4M | $-0.40 |
| Q2 2022 | N/A | $1.4M | $-0.36 |
| Q1 2022 | N/A | -$70.0K | N/A |
| Q3 2021 | $18.9M | $1.4M | N/A |
| Q2 2021 | $18.9M | $1.4M | N/A |
| Q1 2021 | $18.9M | -$70.0K | N/A |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Cullinan Therapeutics, Inc. Dividends, Buybacks & Capital Allocation
CGEM SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Cullinan Therapeutics, Inc. (CIK: 0001789972)
📋 Recent SEC Filings
❓ Frequently Asked Questions about CGEM
What is the AI rating for CGEM?
Cullinan Therapeutics, Inc. (CGEM) has a Combined AI Grade of C from Claude (D) and ChatGPT (C) with 82% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are CGEM's key strengths?
Claude: Strong balance sheet with $75.1M cash and minimal liabilities ($36.8M). Excellent liquidity position with 10.28x current ratio and zero long-term debt. ChatGPT: Very strong liquidity profile with current and quick ratios of 10.25x. Debt-free balance sheet with low liabilities relative to equity.
What are the risks of investing in CGEM?
Claude: Zero revenue indicates pre-commercial status or failed commercialization. Annual cash burn of $46.1M reduces runway to approximately 1.6 years at current rate. ChatGPT: No revenue generation, making the business entirely dependent on external funding or existing capital. Heavy operating and free cash flow burn of roughly $176M annually.
What is CGEM's revenue and growth?
Cullinan Therapeutics, Inc. reported revenue of $0.0.
Does CGEM pay dividends?
Cullinan Therapeutics, Inc. does not currently pay dividends.
Where can I find CGEM SEC filings?
Official SEC filings for Cullinan Therapeutics, Inc. (CIK: 0001789972) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is CGEM's EPS?
Cullinan Therapeutics, Inc. has a diluted EPS of $-2.30.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is CGEM's fundamental grade?
Based on our AI fundamental analysis in June 2026, Cullinan Therapeutics, Inc. has a C grade with 82% confidence. Review the strengths and risks sections above for full context. This is not investment advice.
Is CGEM stock overvalued or undervalued?
Valuation metrics for CGEM: ROE of -13.6% (sector avg: 15%), net margin of N/A (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
What is CGEM's AI grade for 2026?
Our dual AI analysis gives Cullinan Therapeutics, Inc. a combined C grade for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is CGEM's free cash flow?
Cullinan Therapeutics, Inc.'s operating cash flow is $-46.0M, with capital expenditures of $49.0K.
How does CGEM compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin N/A (avg: 12%), ROE -13.6% (avg: 15%), current ratio 10.28 (avg: 2).